Colleen Kane

4.3k total citations · 2 hit papers
46 papers, 3.4k citations indexed

About

Colleen Kane is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Colleen Kane has authored 46 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 16 papers in Hematology and 12 papers in Oncology. Recurrent topics in Colleen Kane's work include Multiple Myeloma Research and Treatments (15 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Parasites and Host Interactions (7 papers). Colleen Kane is often cited by papers focused on Multiple Myeloma Research and Treatments (15 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Parasites and Host Interactions (7 papers). Colleen Kane collaborates with scholars based in United States, Spain and Netherlands. Colleen Kane's co-authors include Daniel R. Neill, Andrew N. J. McKenzie, Christine M. Bucks, Robin J. Flynn, Padraic G. Fallon, Helen E. Jolin, See Heng Wong, Richard Pannell, Maria Daly and Edward J. Pearce and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Colleen Kane

40 papers receiving 3.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity

2010 1.6k citations Daniel R. Neill, See Heng Wong et al. Nature profile →
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

2024 51 citations Paula Rodríguez‐Otero, Niels W.C.J. van de Donk et al. Blood Cancer Journal profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Colleen Kane	2.1k	1.2k	622	559	482	46	3.4k
Margaret Mentink‐Kane	1.6k 0.8×	339 0.3×	422 0.7×	1.4k 2.4×	531 1.1×	40	3.7k
Niamh E. Mangan	2.0k 0.9×	551 0.4×	526 0.8×	713 1.3×	624 1.3×	34	3.9k
Koubun Yasuda	3.1k 1.4×	1.0k 0.8×	961 1.5×	181 0.3×	1.1k 2.4×	57	4.6k
Zoltán Fehérvári	4.7k 2.2×	297 0.2×	284 0.5×	290 0.5×	636 1.3×	89	6.1k
Paola Zaccone	1.3k 0.6×	431 0.3×	131 0.2×	651 1.2×	471 1.0×	56	2.8k
De’Broski R. Herbert	2.3k 1.1×	713 0.6×	495 0.8×	1.3k 2.3×	548 1.1×	80	4.2k
Brandon M. Sullivan	4.6k 2.2×	1.0k 0.8×	793 1.3×	174 0.3×	844 1.8×	26	5.8k
Lucy H. Jackson‐Jones	1.4k 0.7×	231 0.2×	271 0.4×	267 0.5×	445 0.9×	27	2.2k
Steven A. Saenz	3.3k 1.5×	1.6k 1.2×	1.4k 2.3×	211 0.4×	311 0.6×	18	4.4k
Terri M. Laufer	4.2k 2.0×	635 0.5×	582 0.9×	245 0.4×	911 1.9×	58	5.6k

Countries citing papers authored by Colleen Kane

Since Specialization

Citations

This map shows the geographic impact of Colleen Kane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Colleen Kane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Colleen Kane more than expected).

Fields of papers citing papers by Colleen Kane

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Colleen Kane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Colleen Kane. The network helps show where Colleen Kane may publish in the future.

Co-authorship network of co-authors of Colleen Kane

This figure shows the co-authorship network connecting the top 25 collaborators of Colleen Kane. A scholar is included among the top collaborators of Colleen Kane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Colleen Kane. Colleen Kane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rasche, Leo, Carolina Schinke, Cyrille Touzeau, et al.. (2024). Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S240–S240. 5 indexed citations

Schinke, Carolina, Cyrille Touzeau, Monique C. Minnema, et al.. (2024). P-098 Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S99–S99.

Ye, Jing Christine, Noa Biran, Sandhya Nair, et al.. (2024). P-099 Updated Comparative Effectiveness of Talquetamab vs Real-world Physician's Choice of Treatment in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S99–S100. 1 indexed citations

Rasche, Leo, Carolina Schinke, Cyrille Touzeau, et al.. (2024). MM-492 Long-term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S561–S562. 9 indexed citations

Ye, Jing Christine, Noa Biran, Sandhya Nair, et al.. (2024). Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 25(2). 124–134.e5.

Hilder, Brandi, Tara Masterson, Jaszianne Tolbert, et al.. (2024). Evaluation of Drug–Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model. Targeted Oncology. 19(6). 965–979. 1 indexed citations

Rodríguez‐Otero, Paula, Niels W.C.J. van de Donk, Kodandaram Pillarisetti, et al.. (2024). GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood Cancer Journal. 14(1). 24–24. 51 indexed citations breakdown →

Pillai, Rathi N., Suresh S. Ramalingam, Meena Thayu, et al.. (2020). Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414). JTO Clinical and Research Reports. 2(2). 100104–100104. 11 indexed citations

Barlow, Jillian L., S Peel, Jane Fox, et al.. (2013). IL-33 is more potent than IL-25 in provoking IL-13–producing nuocytes (type 2 innate lymphoid cells) and airway contraction. Journal of Allergy and Clinical Immunology. 132(4). 933–941. 318 indexed citations

10.

Kane, Colleen, et al.. (2013). Inhalation Delivery of Protein Therapeutics. Inflammation & Allergy - Drug Targets. 12(2). 81–87. 16 indexed citations

11.

Neill, Daniel R., See Heng Wong, Robin J. Flynn, et al.. (2010). Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 464(7293). 1367–1370. 1632 indexed citations breakdown →

12.

Carvalho, Lucas P., Jie Sun, Colleen Kane, et al.. (2008). Review series on helminths, immune modulation and the hygiene hypothesis: Mechanisms underlying helminth modulation of dendritic cell function. Immunology. 126(1). 28–34. 71 indexed citations

13.

Nissanov, Jonathan, et al.. (2006). Cryoplane fluorescence microscopy. 362–366. 4 indexed citations

14.

Artis, David, Colleen Kane, Colby Zaph, et al.. (2005). Dendritic Cell-Intrinsic Expression of NF-κB1 Is Required to Promote Optimal Th2 Cell Differentiation. The Journal of Immunology. 174(11). 7154–7159. 47 indexed citations

15.

Cervi, Laura, Andrew S. MacDonald, Colleen Kane, Florence Dzierszinski, & Edward J. Pearce. (2004). Cutting Edge: Dendritic Cells Copulsed with Microbial and Helminth Antigens Undergo Modified Maturation, Segregate the Antigens to Distinct Intracellular Compartments, and Concurrently Induce Microbe-Specific Th1 and Helminth-Specific Th2 Responses. The Journal of Immunology. 172(4). 2016–2020. 146 indexed citations

16.

Kane, Colleen, Laura Cervi, Jie Sun, et al.. (2004). Helminth Antigens Modulate TLR-Initiated Dendritic Cell Activation. The Journal of Immunology. 173(12). 7454–7461. 192 indexed citations

17.

Brooks, Virginia L., Lisa S. Welch, & Colleen Kane. (2001). Role of angiotensin II in altered baroreflex function of conscious rabbits during late pregnancy. American Journal of Obstetrics and Gynecology. 184(3). 476–482. 14 indexed citations

18.

Welch, Lisa S., Colleen Kane, & Virginia L. Brooks. (1998). Angiotensin II receptor blockade with losartan does not increase baroreflex gain in conscious, pregnant rabbits. The FASEB Journal. 12(5). 1 indexed citations

19.

Fabian, John R., Colleen Kane, Kenneth J. Abel, & Kenneth W. Gross. (1993). Expression of the Mouse Ren-1 Gene in the Coagulating Gland: Localization and Regulation1. Biology of Reproduction. 48(6). 1383–1394. 15 indexed citations

20.

Cheng, Hwei-Ling, Sara L. Schneider, Colleen Kane, et al.. (1993). TGF-β2 gene and protein expression in maternal and fetal tissues at various stages of murine development. Journal of Reproductive Immunology. 25(2). 133–148. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact